Meta-analysis of 8 controlled T2D clinical trials showed that DPP-4i (sitagliptin and vildagliptin) are associated with significant reductions in TNF-α, an important mediator for T1D-related inflammatory processes (Atkin et al, 2017). The gene discussed is TNF; the disease is type 1 diabetes mellitus.